Richard R Furman

Richard R Furman

UNVERIFIED PROFILE

Are you Richard R Furman?   Register this Author

Register author
Richard R Furman

Richard R Furman

Publications by authors named "Richard R Furman"

Are you Richard R Furman?   Register this Author

100Publications

3310Reads

13Profile Views

Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis.

Mod Pathol 2019 Sep 2. Epub 2019 Sep 2.

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41379-019-0356-zDOI Listing
September 2019

A rare colonic manifestation of chronic lymphocytic leukemia.

Leuk Lymphoma 2019 01 29;60(1):226-229. Epub 2018 Nov 29.

c Division of Gastroenterology and Hepatology , New York Presbyterian Hospital and Weill Cornell Medical Center , New York , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1459612DOI Listing
January 2019

Current trends in the management of Richter's syndrome.

Int J Hematol Oncol 2018 Dec 8;7(4):IJH09. Epub 2019 Jan 8.

Department of Medicine, Division of Hematology & Medical Oncology, New York-Presbyterian Hospital, Weill Cornell Medicine, 525 East 68th Street, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijh-2018-0010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331753PMC
December 2018

Optimal management of the young patient CLL patient.

Best Pract Res Clin Haematol 2018 03 20;31(1):73-82. Epub 2017 Nov 20.

Weill Cornell Medicine, Division of Hematology and Medical Oncology, CLL Research Center, 1305 York Ave, New York, NY, 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2017.10.012DOI Listing
March 2018

The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data.

Leuk Lymphoma 2018 01 2;59(1):256-258. Epub 2017 Jun 2.

a Department of Medicine, Division of Hematology and Oncology , Meyer Cancer Center, Weill Cornell Medicine and New York-Presbyterian Hospital , New York , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1323270DOI Listing
January 2018

Frontline management of chronic lymphocytic leukemia.

Authors:
Richard R Furman

Clin Adv Hematol Oncol 2017 Aug;15 Suppl 10(8):1-20

Weill Cornell Medicine, New York-Presbyterian, New York, New York.

View Article

Download full-text PDF

Source
August 2017

Extended follow-up with the Bruton's tyrosine kinase inhibitor ibrutinib in previously treated Waldenström's macroglobulinemia.

Leuk Lymphoma 2017 06 26;58(6):1502-1505. Epub 2016 Oct 26.

b Pharmacyclics LLC, an AbbVie Company , Sunnyvale , CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2016.1247957DOI Listing
June 2017

Role of Surveillance Imaging in Patients With Peripheral T-Cell Lymphoma.

Clin Lymphoma Myeloma Leuk 2016 Mar 21;16(3):117-21. Epub 2015 Dec 21.

Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2015.12.006DOI Listing
March 2016

Management of chronic lymphocytic leukemia.

Am Soc Clin Oncol Educ Book 2015 :164-75

From Ulm University, Ulm, Germany; Weill Cornell Medical College, New York, NY; University of Rochester, Rochester, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2015.35.164DOI Listing
February 2016

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

N Engl J Med 2016 Jan 7;374(4):323-32. Epub 2015 Dec 7.

From the Division of Hematology, Department of Internal Medicine, Ohio State University (J.C. Byrd, J.A.J., F.T.A., J.W., A.J.J.), and the Department of Veterinary Biosciences, College of Veterinary Medicine (B.H.) - both in Columbus; UC Irvine Health Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange (S.O.); University of Oxford, Oxford (A.S.), NHS Foundation Trust, King's College Hospital, London (S.D.), and the Department of Haematology, St. James's University Hospital, Leeds (P.H.) - all in the United Kingdom; Northwest Medical Specialties, Tacoma (J.C.), and the Swedish Cancer Institute, Seattle (J.M.P.) - both in Washington; the Department of Leukemia, Division of Cancer Medicine, University of Texas, and M.D. Anderson Cancer Center - both in Houston (W.G.W.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); Huntsman Cancer Institute, University of Utah, Salt Lake City (D.M.S.); Università Vita-Salute San Raffaele and Istituto Scientifico San Raffaele, Milan (P.G.); Hofstra North Shore-LIJ School of Medicine, Chronic Lymphocytic Leukemia Research and Treatment Center, Lake Success (J.C. Barrientos), and the Department of Pathology and Cell Biology, Columbia University Medical Center (T.G.D.), and New York-Presbyterian/Weill Cornell Medical Center, New York (R.R.F.) - all in New York; and Acerta Pharma, Oss, the Netherlands (D.J., J.H., X.W., A.K., B.J.L., T.C., M.F., J.M., A.H., W.R., R.I.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1509981DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862586PMC
January 2016

Idelalisib-associated Colitis: Histologic Findings in 14 Patients.

Am J Surg Pathol 2015 Dec;39(12):1661-7

*Department of Pathology and Laboratory Medicine †Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000522DOI Listing
December 2015

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.

N Engl J Med 2015 Nov;373(19):1835-44

From the Meyer Cancer Center, Division of Hematology and Medical Oncology (J.R., P.M., R.R.F., A.R., J.L., O.K., M.C., J.P.L.), and Division of Biostatistics and Epidemiology (P.C.), Weill Cornell Medical College and New York-Presbyterian Hospital, New York; Moffitt Cancer Center, Tampa, FL (B.S.); University of Pennsylvania Abramson Cancer Center, Philadelphia (S.J.S., J.S.); and the University of Chicago Medical Center, Chicago (S.M.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1505237DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710541PMC
November 2015

Extracorporeal membrane oxygenation as a bridge to chemotherapy in an Orthodox Jewish patient.

Oncologist 2014 Sep 5;19(9):985-9. Epub 2014 Aug 5.

Division of Medical Ethics, Department of Anesthesia, and Division of Hematology and Medical Oncology, Center for Lymphoma and Myeloma, Weill Cornell Medical College and New York Presbyterian Hospital, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153457PMC
September 2014

To the end of chronic lymphocytic leukemia: what should be the role of allogeneic transplant?

Leuk Lymphoma 2014 Jun;55(6):1221-2

Hematology/Oncology, Weill Cornell Medical College , New York, NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.903394DOI Listing
June 2014

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

N Engl J Med 2014 Jun 28;370(24):2286-94. Epub 2014 May 28.

From the Division of Hematology, Department of Internal Medicine (J.A.W., T.-M.L., A.S.R., S.M.J., K.A.B., A.L., A.J.J., J.C. Byrd), the Department of Biomedical Informatics (H.G.O., A.S.Y.), and the Department of Pathology (G.L.), Ohio State University, Columbus; the Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medical College, New York (R.R.F.); the Division of Molecular Genetics, German Cancer Research Center, Heidelberg (M.Z., P.L.), and the Department of Internal Medicine III, University of Ulm, Ulm (S.S.) - both in Germany; Pharmacyclics, Sunnyvale, CA (L.X., D.H.-H.L., S.M.S., D.F.J., J.J.B., B.Y.C.); the Duke Cancer Institute, Duke University, Durham, NC (S.S.D., J.Z.); the Division of Hematology-Oncology, Department of Medicine, Hofstra North Shore-LIJ School of Medicine, New Hyde Park, NY (J.C. Barrientos); and Janssen Research and Development, Beerse, Belgium (M.V.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1400029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144824PMC
June 2014

Long-term follow-up of R-CHOP with bevacizumab as initial therapy for mantle cell lymphoma: clinical and correlative results.

Clin Lymphoma Myeloma Leuk 2014 Apr 18;14(2):107-13. Epub 2013 Nov 18.

Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2013.10.002DOI Listing
April 2014

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

N Engl J Med 2014 Mar 22;370(11):997-1007. Epub 2014 Jan 22.

Weill Cornell Medical College (R.R.F.), Memorial Sloan-Kettering Cancer Center (A.D.Z.), the Department of Medicine, and Columbia University Medical Center (N.L.) - all in New York; U.S. Oncology Research, Springfield, OR (J.P.S.); Stanford University School of Medicine, Stanford (S.E.C.), and Gilead Sciences, Foster City (M.A., D.M.J., L.L.M., D.L., T.M.J., R.D.D.) - both in California; Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC (B.D.C.); Fred Hutchinson Cancer Research Center, University of Washington, Seattle (J.M.P.); St. James's University Hospital, Leeds (P.H.), and Royal Liverpool University Hospital, Liverpool (A.R.P.) - both in the United Kingdom; Hofstra North Shore-LIJ School of Medicine, New Hyde Park, New York (J.C.B.); University of California San Diego, Moores Cancer Center, La Jolla (T.J.K.); Sarah Cannon Research Institute, Nashville (I.F.); Universita Vita-Salute San Raffaele, Instituto Scientifico San Raffaele, Milan (P.G.); David Geffen School of Medicine, University of California Los Angeles, Los Angeles (H.E.); Florida Cancer Specialists, Englewood (T.E.); Centre Hospitalier Lyon-Sud, Pierre-Bénite, France (B.C.); Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago (S.M.); University of Ulm, Ulm (S.S.), and University of Cologne, Cologne (P.C., M.H.) - both in Germany; and University of Texas M.D. Anderson Cancer Center, Houston (S.M.O.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1315226DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161365PMC
March 2014

Highlights in B-cell malignancies from the 2013 American Society of Hematology annual meeting and exposition: commentary.

Authors:
Richard R Furman

Clin Adv Hematol Oncol 2014 Mar;12 Suppl 8(3):19-23

Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
March 2014

Unmet needs in the treatment of chronic lymphocytic leukemia: introduction.

Authors:
Richard R Furman

Clin Adv Hematol Oncol 2014 Jan;12 Suppl 3(1):2-5

Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
January 2014

Prognostic markers and stratification of chronic lymphocytic leukemia.

Authors:
Richard R Furman

Hematology Am Soc Hematol Educ Program 2010 ;2010:77-81

Division of Hematology/Oncology, Weill Cornell Medical College, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2010.1.77DOI Listing
April 2011

Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.

J Clin Oncol 2011 Feb 28;29(6):690-7. Epub 2010 Dec 28.

Center for Lymphoma and Myeloma, Weill Cornell Medical College, 525 East 68th St, Starr 340, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2010.31.1142DOI Listing
February 2011

Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.

Cancer 2010 Dec 27;116(23):5432-9. Epub 2010 Jul 27.

Center for Lymphoma and Myeloma, Weill Cornell Medical College and New York Presbyterian Hospital, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25509DOI Listing
December 2010

Cutaneous CD4+ CD56+ hematologic malignancies.

J Am Acad Dermatol 2010 Aug 11;63(2):292-308. Epub 2010 Jun 11.

Department of Pathology, Weill Medical College of Cornell University, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2009.08.044DOI Listing
August 2010

New agents in early clinical trials for CLL therapy.

Authors:
Richard R Furman

Clin Adv Hematol Oncol 2010 Jul;8(7):475-6

CLL Research Center, Weill Medical College, New York, New York, USA.

View Article

Download full-text PDF

Source
July 2010

A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia.

Leuk Lymphoma 2010 Feb;51(2):228-35

Division of Hematology/Oncology, Weill Cornell Medical College, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428190903440946DOI Listing
February 2010

Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.

Clin Cancer Res 2010 Jan 12;16(2):587-99. Epub 2010 Jan 12.

Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-1519DOI Listing
January 2010

Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.

J Clin Oncol 2009 Sep 27;27(26):4371-7. Epub 2009 Jul 27.

Division of Oncology, Stanford University Medical Center, 875 Blake Wilbur Dr, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.21.3017DOI Listing
September 2009

Durable complete remissions in HIV-associated Hodgkin lymphoma after treatment with only one cycle of chemotherapy complicated by sepsis.

Clin Lymphoma Myeloma 2009 Jun;9(3):247-9

Division of Hematology and Medical Oncology, Center for Lymphoma and Myeloma, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S155791901170201
Publisher Site
http://dx.doi.org/10.3816/CLM.2009.n.049DOI Listing
June 2009